{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T20:01:39Z","timestamp":1780948899809,"version":"3.54.1"},"reference-count":16,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T00:00:00Z","timestamp":1772668800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","japha.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Pharmacists Association"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.japh.2026.103072","type":"journal-article","created":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T23:28:03Z","timestamp":1772926083000},"page":"103072","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Implementing an electronic flowsheet for biologics requiring infusions and injections in inflammatory bowel disease"],"prefix":"10.1016","volume":"66","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-0698-4330","authenticated-orcid":false,"given":"Jessica","family":"Fann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8458-141X","authenticated-orcid":false,"given":"Miranda","family":"Murray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8171-5766","authenticated-orcid":false,"given":"Josh","family":"DeClercq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2544-7090","authenticated-orcid":false,"given":"Leena","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3393-7863","authenticated-orcid":false,"given":"Kristen","family":"Whelchel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.japh.2026.103072_bib1","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S2468-1253(21)00377-0","article-title":"Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis","volume":"7","author":"Lasa","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.japh.2026.103072_bib2","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1136\/gutjnl-2022-328052","article-title":"Efficacy of biological therapies and small molecules in induction and maintenance of remission in luminal Crohn's disease: systematic review and network meta-analysis","volume":"72","author":"Barberio","year":"2023","journal-title":"Gut"},{"key":"10.1016\/j.japh.2026.103072_bib3","series-title":"Skyrizi (Risankizumab) [package insert]","year":"2024"},{"key":"10.1016\/j.japh.2026.103072_bib4","series-title":"Stelara (Ustekinumab) [package insert]","year":"2024"},{"issue":"8","key":"10.1016\/j.japh.2026.103072_bib5","first-page":"764","article-title":"Ustekinumab infusion to subcutaneous transition: coordinating care and identifying potential gaps","volume":"31","author":"Renfro","year":"2025","journal-title":"J Manag Care Spec Pharm"},{"issue":"sup1","key":"10.1016\/j.japh.2026.103072_bib6","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1080\/21556660.2018.1521080","article-title":"Ensuring continuity of care for patients transitioning from intravenous to subcutaneous therapy at a health system owned specialty pharmacy","volume":"7","author":"Peterson","year":"2018","journal-title":"J Drug Assess"},{"issue":"12","key":"10.1016\/j.japh.2026.103072_bib7","doi-asserted-by":"crossref","first-page":"4331","DOI":"10.1007\/s10620-023-08098-7","article-title":"Insurance approval delay of biologic therapy dose escalation associated with disease activity in patients with inflammatory bowel disease","volume":"68","author":"Shah","year":"2023","journal-title":"Dig Dis Sci"},{"issue":"3","key":"10.1016\/j.japh.2026.103072_bib8","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2021-052501","article-title":"Delays related to prior authorization in inflammatory bowel disease","volume":"149","author":"Constant","year":"2022","journal-title":"Pediatrics"},{"issue":"11","key":"10.1016\/j.japh.2026.103072_bib9","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1002\/acr.24062","article-title":"Treatment delays associated with prior authorization for infusible medications: a cohort study","volume":"72","author":"Wallace","year":"2020","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"3","key":"10.1016\/j.japh.2026.103072_bib10","doi-asserted-by":"crossref","DOI":"10.14309\/ctg.0000000000000808","article-title":"Higher rates of delay in starting advanced inflammatory bowel disease therapies linked to insurance delays, intravenous infusions, and lack of pharmacy support","volume":"16","author":"Gottesman","year":"2025","journal-title":"Clin Transl Gastroenterol"},{"issue":"1","key":"10.1016\/j.japh.2026.103072_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.japh.2024.102262","article-title":"Implementing a letter template to expedite specialty medication appeal letter submission","volume":"65","author":"Fann","year":"2025","journal-title":"J Am Pharm Assoc (2003)"},{"issue":"4","key":"10.1016\/j.japh.2026.103072_bib12","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1097\/MOG.0000000000000642","article-title":"The burden of cost in inflammatory bowel disease: a medical economic perspective","volume":"36","author":"Beard","year":"2020","journal-title":"Curr Opin Gastroenterol"},{"issue":"3","key":"10.1016\/j.japh.2026.103072_bib13","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1007\/s11894-024-00916-w","article-title":"Advanced therapies for inflammatory bowel disease: navigating payor and financial challenges","volume":"26","author":"Whitmire","year":"2024","journal-title":"Curr Gastroenterol Rep"},{"issue":"Suppl 2","key":"10.1016\/j.japh.2026.103072_bib14","doi-asserted-by":"crossref","first-page":"S55","DOI":"10.1093\/ajhp\/zxac354","article-title":"Development and implementation of a laboratory monitoring dashboard to reduce treatment gaps in inflammatory bowel disease","volume":"80","author":"Kozlicki","year":"2023","journal-title":"Am J Health Syst Pharm"},{"issue":"7","key":"10.1016\/j.japh.2026.103072_bib15","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1001\/jamainternmed.2023.1829","article-title":"Health insurer strategies to reduce specialty drug spending-copayment adjustment and alternative funding programs","volume":"183","author":"Zuckerman","year":"2023","journal-title":"JAMA Intern Med"},{"issue":"8","key":"10.1016\/j.japh.2026.103072_bib16","first-page":"883","article-title":"A primer on copay accumulators, copay maximizers, and alternative funding programs","volume":"30","author":"Choi","year":"2024","journal-title":"J Manag Care Spec Pharm"}],"container-title":["Journal of the American Pharmacists Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1544319126000579?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1544319126000579?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T19:38:22Z","timestamp":1780947502000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1544319126000579"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":16,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S1544319126000579"],"URL":"https:\/\/doi.org\/10.1016\/j.japh.2026.103072","relation":{},"ISSN":["1544-3191"],"issn-type":[{"value":"1544-3191","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Implementing an electronic flowsheet for biologics requiring infusions and injections in inflammatory bowel disease","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Pharmacists Association","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.japh.2026.103072","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of American Pharmacists Association\u00ae.","name":"copyright","label":"Copyright"}],"article-number":"103072"}}